BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined
with platinum-based chemotherapy ± Bevacizumab Phase III study: a confirmatory study to
evaluate the safety and efficacy of BAT1308 combined with platinum-based chemotherapy ±
Bevacizumab as first-line therapy for PD-L1-positive (CPS ≥ 1) persistent, recurrent or
metastatic cervical cancer